Macrolides are a family of antibiotics built around a large ring-shaped chemical structure, used to treat everything from strep throat and pneumonia to skin infections and sexually transmitted diseases. Erythromycin, the first to reach clinical use, arrived in the early 1950s; azithromycin and clarithromycin followed decades later with improved tolerability and dosing convenience. What makes macrolides genuinely interesting, though, is that they do more than just kill bacteria. They calm inflammation, speed up a sluggish stomach, and accumulate inside your own immune cells in ways most antibiotics cannot.
What Gives a Macrolide Its Name
The word “macrolide” refers to a macrocyclic lactone ring, a large loop of carbon and oxygen atoms to which one or more sugar molecules are attached.1PubMed Central. The macrolide antibiotic renaissance Ring size varies. The antibiotics most people are prescribed contain either 14-membered or 15-membered rings.2PubMed. 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity Erythromycin and clarithromycin have 14-membered rings; azithromycin has a 15-membered ring that includes a nitrogen atom, which is why it is sometimes called an “azalide.” Sixteen-membered-ring macrolides also exist and are used in some countries but are less common in the United States and Europe. The sugar molecules dangling off the ring are critical because they help the drug bind to its bacterial target and also influence how well the drug survives stomach acid.3Journal of Antimicrobial Chemotherapy. Chemistry and mode of action of macrolides
How They Stop Bacteria
Macrolides work by jamming a critical piece of bacterial machinery: the ribosome, the structure that reads genetic instructions and assembles proteins from them. Specifically, macrolides lodge themselves inside the exit tunnel through which newly made protein chains emerge from the ribosome. By partially blocking that tunnel, they stall production.4PubMed Central. How Macrolide Antibiotics Work A bacterium that cannot make proteins cannot grow, reproduce, or maintain its own cell wall. At typical doses macrolides are bacteriostatic, meaning they stop bacterial growth rather than directly bursting cells open. At higher concentrations, or against certain species, they can be bactericidal.
Human ribosomes are structurally different enough that macrolides do not interfere with our own protein production, which is why these drugs can target bacteria without poisoning the patient’s cells.
What Macrolides Are Prescribed For
Macrolides are most reliably active against Gram-positive bacteria such as streptococci and staphylococci, along with atypical pathogens like Mycoplasma and Chlamydia. They have more limited activity against Gram-negative species.5Nature Index. Macrolide Antibiotics and Antibacterial Activity In practice, doctors reach for macrolides in several common situations:
- Community-acquired pneumonia: Guidelines for severe cases recommend empiric coverage that includes macrolides (or tetracyclines or fluoroquinolones) because atypical pathogens are a frequent cause.6PubMed Central. Atypical Pathogens in Adult Community-Acquired Pneumonia and Implications for Empiric Antibiotic Treatment: A Narrative Review
- Strep throat and skin infections: Azithromycin or clarithromycin is a standard alternative for people allergic to penicillin.
- Sexually transmitted infections: Azithromycin is widely used for chlamydia and was, for many years, part of dual therapy for gonorrhea.
- Ear infections and sinusitis: Clarithromycin and azithromycin are common second-line options, particularly in children who cannot tolerate amoxicillin.
Azithromycin became especially popular because of its convenient dosing. A five-day course, or even a single large dose for some infections, replaces the multiple-times-per-day schedules that erythromycin and clarithromycin require. That convenience owes a lot to how the drug behaves inside the body.
Why Azithromycin Lingers in Your Tissues
Most antibiotics float around in your bloodstream and wash out within hours. Azithromycin does something unusual: it piles up inside cells, particularly white blood cells and tissue cells like fibroblasts. In lab experiments with human fibroblasts, azithromycin accumulated to concentrations roughly 21 times higher than erythromycin achieved under the same conditions.7PubMed Central. Intracellular accumulation of azithromycin by cultured human fibroblasts In phagocytic immune cells such as macrophages and neutrophils, azithromycin has been measured at concentrations up to 226 times the level outside the cell, and these concentration gradients far exceed those seen with erythromycin.8PubMed Central. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection
Of all the body compartments measured, white blood cells had the highest azithromycin concentrations, confirming the drug’s tendency to concentrate intracellularly.9PubMed Central. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy The practical upshot is that infected tissues end up bathed in drug for days after the last dose. White blood cells carry azithromycin to infection sites and slowly release it, which is why a short course can keep working long after you stop taking the pills. Fibroblasts, present almost everywhere in the body, serve as additional drug reservoirs.10PubMed Central. Intracellular accumulation of azithromycin by cultured human fibroblasts
The Anti-Inflammatory Side of Macrolides
One of the more surprising chapters in macrolide history began in Japan in the late 1980s. Patients with diffuse panbronchiolitis, a progressive inflammatory lung disease that had previously carried a poor prognosis, started responding dramatically to long-term low-dose erythromycin. In one early study, 16 of 19 patients experienced relief from productive cough and shortness of breath, with visible improvement on chest X-rays.11PubMed. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis The doses used were too low to explain the benefit through bacterial killing alone, and the effect was too consistent to be coincidence.
It turned out that macrolides can dial down inflammation independently of their antibacterial activity. They influence how immune cells behave, reduce the production of inflammatory signaling molecules, and help control excess mucus production.12PubMed. Long-term macrolide treatment for chronic respiratory disease Azithromycin in particular appears to have a biphasic effect on inflammation: it may initially boost the body’s early defensive response and then, over the following days, tamp down the sustained local inflammation that causes tissue damage.13PubMed. Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
This discovery opened the door to studying macrolides in other chronic lung diseases. The best-studied is cystic fibrosis, where six randomized controlled trials have shown evidence of benefit from long-term macrolide therapy.14PubMed. Long-term macrolide treatment for chronic respiratory disease Macrolides have also been explored in bronchiectasis, chronic obstructive pulmonary disease, and asthma. The concept of using a “low-dose maintenance” macrolide, prescribed not to treat an acute infection but to control chronic inflammation, is now an accepted strategy for certain conditions.15Journal of Antimicrobial Chemotherapy. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis
Macrolides and Gut Motility
If you have ever taken erythromycin and noticed your stomach churning, that is not a side effect in the usual sense. Erythromycin mimics a natural gut hormone called motilin by binding directly to motilin receptors on the smooth muscle of the gastrointestinal tract.16PubMed. Improvement of gastric emptying in diabetic gastroparesis by erythromycin This triggers strong contractions in the stomach and upper intestine and improves the coordination between the stomach and the duodenum.17Gastroenterology. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination
For most patients this just means nausea or stomach cramps. But for people with gastroparesis, a condition where the stomach empties too slowly, erythromycin at low doses is actually used therapeutically to get the stomach moving again. Experiments in transgenic mice carrying human motilin receptors confirmed that erythromycin’s ability to speed gastric emptying depends specifically on those receptors; mice lacking them showed no response to the drug.18PLoS ONE. Characterization of the gastric motility response to human motilin and erythromycin in human motilin receptor-expressing transgenic mice Azithromycin and clarithromycin have a weaker motilin-receptor effect, which is one reason they tend to be easier on the stomach than erythromycin.
Drug Interactions and Heart Risks
Erythromycin and clarithromycin inhibit a key liver enzyme called CYP3A4, which is responsible for processing a large share of all medications.19PubMed. Macrolide antibacterials. Drug interactions of clinical significance When this enzyme is blocked, other drugs that rely on it for clearance build up in the bloodstream. The consequences can be serious. Blood thinners, certain heart medications, anti-seizure drugs, and some cholesterol-lowering statins can all rise to dangerous levels if taken alongside erythromycin or clarithromycin.20PubMed. Drug interactions of macrolides: emphasis on dirithromycin Azithromycin is substantially less likely to cause these interactions because it has much weaker effects on CYP3A4.
Separately, macrolides as a class can affect the heart’s electrical system. They are associated with a type of abnormal heart rhythm called torsades de pointes, and the FDA has strengthened warnings on azithromycin labels in response to observational data linking it to cardiac arrhythmias.21PubMed Central. Macrolide antibiotics and the risk of cardiac arrhythmias For most healthy people taking a standard course, the absolute risk is very small. The concern is mainly for patients who already have heart rhythm problems, low potassium or magnesium levels, or who are taking other drugs that also affect the heart’s electrical cycle.
Hearing Changes
A less well-known side effect of macrolides is their association with hearing loss. A systematic review and meta-analysis found that macrolide use was linked to a roughly 25 percent higher odds of ototoxicity symptoms compared to controls. The signal was statistically significant in randomized controlled trials and case-control studies.22Scientific Reports. Increased risk of hearing loss associated with macrolide use: a systematic review and meta-analysis Another systematic review found that sensorineural hearing loss has been reported with both oral and intravenous macrolide use at both standard and elevated doses.23PubMed. Macrolide-associated sensorineural hearing loss: A systematic review
In most cases the hearing changes are reversible once the drug is stopped, and they appear more common at higher doses or with intravenous administration. Still, the finding is worth knowing about. If you notice muffled hearing or ringing in the ears during a macrolide course, it is worth mentioning to your prescriber rather than assuming it is unrelated.
How Bacteria Fight Back
Resistance to macrolides is a growing problem, and bacteria have evolved more than one way to dodge them. The most potent form involves a group of genes called erm genes. These genes encode enzymes that chemically modify the ribosomal target site where macrolides bind, changing its shape enough that the drug can no longer attach. This confers high-level resistance.24PubMed. Macrolide resistance mechanisms in Gram-positive cocci
A second major strategy is efflux. Bacteria carry pump proteins, encoded by genes like mef and msr, that actively flush macrolides out of the cell before they can reach the ribosome. These efflux genes are increasingly found on mobile genetic elements, meaning they can jump between bacterial species.25PLOS ONE. Transcriptional Attenuation Controls Macrolide Inducible Efflux and Resistance in Streptococcus pneumoniae and in Other Gram-Positive Bacteria Containing mef/mel(msr(D)) Elements Erythromycin and azithromycin interact with these pumps differently. Modeling studies suggest erythromycin binds more tightly to the MefA membrane component than azithromycin does, while the reverse is true for the cytoplasmic counterpart, which may partly explain why their clinical susceptibility profiles diverge against resistant strains.26ACS Omega. Structure Elucidation and Interaction Dynamics of MefA-MsrD Efflux Proteins in Streptococcus pneumoniae: Impact on Macrolide Susceptibility
The real-world consequence is that in many parts of the world, a substantial proportion of common respiratory pathogens are now resistant to standard macrolides. In some regions, resistance rates for Group A streptococcus and Streptococcus pneumoniae are high enough that clinicians have to think carefully before choosing azithromycin as a first-line option.
Ketolides and the Next Generation
Ketolides were designed specifically to get around macrolide resistance. They are semi-synthetic derivatives of erythromycin in which one of the sugar molecules, L-cladinose, has been stripped off and replaced with a keto group. That seemingly small change has large consequences: the modified structure does not trigger the inducible resistance mechanism that many Gram-positive cocci use to resist standard macrolides.27Clinical Microbiology and Infection. Ketolides—telithromycin, an example of a new class of antibacterial agents The keto group also makes the molecule more stable in acid, improving oral absorption.28PubMed. Structure-activity relationships of ketolides vs. macrolides
Telithromycin, the first ketolide to reach the market, was effective against macrolide-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.29PubMed. Ketolides: the future of the macrolides? However, it ran into safety concerns, including rare but serious liver toxicity, which led to restrictions on its approved indications. The story of telithromycin illustrates a recurring tension in antibiotic development: building a drug that outsmarts resistance is only half the problem; keeping it safe enough for widespread outpatient use is the other half. Newer ketolide candidates continue to be explored, with researchers trying to preserve the anti-resistance advantages while improving the side-effect profile.
Fidaxomicin, a Narrow-Spectrum Cousin
Fidaxomicin is technically a macrocyclic lactone, so it shares structural ancestry with macrolides, but its mechanism is completely different. Instead of blocking the ribosome, fidaxomicin inhibits a bacterial RNA polymerase, the enzyme that copies DNA into RNA, at a site distinct from where other RNA-polymerase-targeting drugs like rifamycins act.30Clinical Infectious Diseases. Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection It was the first new antibiotic approved by the FDA for Clostridioides difficile infection in over 25 years.
What makes fidaxomicin noteworthy is its extreme selectivity. It is bactericidal against C. difficile and has a prolonged post-antibiotic effect lasting about 10 hours, but it barely touches normal gut flora, including anaerobes and Gram-negative bacteria that form the protective community keeping C. difficile in check.31PubMed Central. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection Because the drug is essentially not absorbed from the gut, it stays concentrated where the infection is. In clinical trials fidaxomicin matched vancomycin for initial cure rates and was superior for preventing recurrence.32Clinical Infectious Diseases. Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection Preventing recurrence matters a great deal for C. difficile, where repeat episodes are common and increasingly dangerous.
Macrolides in Agriculture
Macrolides are not only used in humans. They are widely used in livestock, both to treat infections and, in some production systems, at low doses mixed into feed. Low-dose, prolonged exposure is exactly the scenario most likely to breed resistant bacteria. Both in-feed medication and long-acting injectable formulations keep active drug concentrations low in animal tissues for extended periods, raising concerns about resistance development among food animal pathogens, including some that can transfer to humans.33PubMed. Macrolides and lincosamides in cattle and pigs: use and development of antimicrobial resistance
Resistance genes selected in animal bacteria do not stay confined to the barn. Horizontal gene transfer, the same mobile genetic elements that spread efflux pumps among human pathogens, can shuttle resistance between animal and human bacterial populations. The misuse and overuse of antibiotics in livestock, particularly long-term sub-therapeutic use, places selective pressure that accelerates this process.34PubMed Central. Livestock Antibiotics Use and Antimicrobial Resistance Regulatory approaches vary by country: the European Union banned antibiotic growth promoters years ago, while other regions have been slower to restrict sub-therapeutic use.
Macrolides in the Water
Macrolides do not just vanish after they leave the body. Wastewater treatment plants only partially remove them, so they reach rivers, lakes, and coastal waters at detectable concentrations.35Environmental Science & Technology. Occurrence and Fate of Macrolide Antibiotics in Wastewater Treatment Plants and in the Glatt Valley Watershed, Switzerland A global review found macrolides detected in water bodies at average or median concentrations reaching nearly 4,000 nanograms per liter in the most polluted sites, mainly downstream of wastewater treatment plants and densely populated areas.36PubMed. Global review of macrolide antibiotics in the aquatic environment: Sources, occurrence, fate, ecotoxicity, and risk assessment
Among the macrolides monitored in wastewater, azithromycin is persistently detected. At one small treatment plant, removal efficiency for azithromycin was only about 47 percent, meaning roughly half of what entered the plant passed through into receiving waters.37PubMed. Contamination profiles and mass loadings of macrolide antibiotics and illicit drugs from a small urban wastewater treatment plant In rivers, elimination along even a 36-kilometer stretch was less than 20 percent for clarithromycin.38Environmental Science & Technology. Occurrence and Fate of Macrolide Antibiotics in Wastewater Treatment Plants and in the Glatt Valley Watershed, Switzerland
The environmental concern is twofold. First, macrolide residues in water are toxic to aquatic organisms, particularly microalgae, which are sensitive at concentrations well below those that affect fish or crustaceans. Over half the water bodies studied in the global review posed a medium-to-high risk to microalgae.39PubMed. Global review of macrolide antibiotics in the aquatic environment: Sources, occurrence, fate, ecotoxicity, and risk assessment Second, antibiotics in the environment provide low-level selective pressure that can promote resistance in environmental bacteria, potentially feeding resistance back into clinically relevant species. This connection between wastewater, agriculture, and human medicine is exactly the kind of loop that makes antibiotic resistance such a stubborn global problem.
Where Macrolides Come From in Nature
Most macrolide antibiotics trace their origins to soil-dwelling bacteria in the genus Streptomyces. These organisms produce macrolides as secondary metabolites, assembled by large enzyme complexes called polyketide synthases. Streptomyces species use different types of these enzyme systems to stitch together the carbon chains that form the lactone ring backbone.40PubMed Central. Biosynthesis of Polyketides in Streptomyces The gene clusters encoding these enzyme complexes can be enormous. In one species, Streptomyces ambofaciens, researchers activated a silent gene cluster spanning almost 150 kilobases, nine genes of which encoded polyketide synthases, and discovered four previously unknown 51-membered macrolides named stambomycins.41PubMed Central. Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens
The fact that many of these biosynthetic gene clusters are “silent,” meaning the genes exist but are not actively producing anything under normal lab conditions, is tantalizing. It suggests that soil bacteria harbor a much larger library of macrolide-like molecules than we have discovered so far. Activating silent clusters through genetic manipulation is now an active area of natural-product drug discovery, with the hope of finding novel scaffolds that could overcome existing resistance or target entirely new bacterial vulnerabilities.